Navigation Links
ISTA Pharmaceuticals Announces Positive Preliminary Results from,Ecabet Sodium Phase IIb Study

ther development of ecabet sodium (including but not limited to statements that ISTA will complete its analysis and confirm its preliminary Phase IIb findings, meet with the FDA, and initiate a Phase III study with respect to ecabet sodium during 2008), the potential of ecabet sodium to treat dry eye syndrome and its potential advantages over other currently marketed dry eye products, ISTA's statements about potential future objective endpoints for Phase III studies and ISTA's goals of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company in the U.S. are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. Such statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: the risk that full analysis of the Phase IIb data or further testing of ecabet sodium, will not reflect the preliminary Phase IIb results, or support any or all of the conclusions provided in this press release; delays, risks and uncertainties related to ISTA's ecabet sodium development program (including the difficulty of predicting the timing or outcome of ISTA's product development efforts and the FDA or other governmental agency approval or actions); uncertainties and risks regarding market acceptance of ISTA's approved products and the impact of competitive products and pricing; risks and uncertainties related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products, and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property r
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:7/23/2014)... and MOUNTAIN VIEW, Calif. , July ... leader in translational preclinical research, today unveiled their new ... signaling the transformation of Surpass, corporate culture to one ... our customers. This press release comes on the heels ... were added to the Silicon Valley Team:  David Craig, ...
(Date:7/23/2014)... 23, 2014 On Tuesday, July 1, ... suit in the 116 th Judicial District ... against RegenLab USA, LLC ("Defendant") for ... Relationships through false and misleading actions, fraud, ... Disparagement through libel, disparagement, defamation, misrepresentation, and ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Use of Risk ... programs to delay generic market entry results in $5.4 ... new survey and analysis by economic consulting firm ... - http://photos.prnewswire.com/prnh/20140723/129680 Required by the ... and biologics, REMS programs are intended to improve drug ...
Breaking Medicine Technology:SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry 2
... Inc ., a clinical-stage epigenetics oncology company, announced today ... with entinostat in combination and as a single agent ... San Antonio Breast Cancer Symposium ... phase 2 study of exemestane with and without entinostat ...
... MALVERN, Pa., Dec. 1, 2011 Auxilium Pharmaceuticals, Inc. ... today announced that the first patient has been dosed ... (collagenase clostridium histolyticum) for the treatment of idiopathic ... Shoulder syndrome. (Logo:  http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ...
Cached Medicine Technology:Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 2Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 3Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 4Multiple Data Presentations on Syndax Pharmaceutical's Entinostat at Upcoming Scientific Conferences 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 2Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 3Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 4Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 5Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome 6
(Date:7/23/2014)... of research suggesting a safe and effective role ... cancer, with fewer detrimental side effects and improved ... study will be published in final format today ... Endocrinology . , Breast cancer is the most ... States. Approximately 70% of breast cancers are diagnosed ...
(Date:7/23/2014)... July 23, 2014 Rich Dad® Education, a ... of their charity yard sale to support Habit for Humanity ... 100% of the proceeds will be donated to Habitat for ... are being donated to the Habitat for Humanity ReStore thrift ... 33903. , One of the highlights of the yard ...
(Date:7/23/2014)... York (PRWEB) July 23, 2014 Thousands ... to move forward in a federal multidistrict litigation underway ... Liebhard LLP reports. According to an Order dated July ... hospital’s bid for payment of a $1,000 fee for ... implant. , Among other things, the Order noted ...
(Date:7/23/2014)... better treating the pernicious disorders of obesity and dementia ... American University,s Center for Behavioral Neuroscience. In the paper, ... aimed at areas of the brain responsible for memory ... could play a role in reducing certain dementias., "In ... measures often fall short. This is a new way ...
(Date:7/23/2014)... Olympic gold medal-winning speed skater Chad ... Friday, July 18. Hedrick visited Roanoke as the special ... an Olympic-style event celebrating its 25th Anniversary in 2014. ... premier sponsor of the Commonwealth Games, which like Foot ... and all activity levels. , Hedrick, a native of ...
Breaking Medicine News(10 mins):Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Rich Dad Education Charity Yard Sale Raises Over $650 for Habitat for Humanity of Lee and Hendry Counties 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Hip Lawsuits Move Forward, as Federal Judge Denies Hospital Bid for $1000 Explant Fee, Bernstein Liebhard LLP Reports 4Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:US Olympian Chad Hedrick Visits Foot Levelers 2
... , ... Care of Serious Illness is the first book to provide a comprehensive look at the ... E. Meier, Stephen L. Isaacs, Robert Hughes (Editors) , ... New York, NY (Vocus) April 1, 2010 -- Palliative Care: Transforming ...
... they know how cytomegalovirus continues to re-infect people , THURSDAY, ... how a virus known as cytomegalovirus (CMV), which infects up ... re-infects people again and again even though their immune systems ... always make people ill, but certain people, such as newborns ...
... SNM and the Radiological Society of North America (RSNA) ... at the Natcher Conference Center of the National Institutes ... workshop will focus on general issues of standardization to ... and analysis of images in clinical trials. The second ...
... beat vitamin B for those with scent-robbing viral infection, ... Acupuncture may help people who lose their sense of ... a new study, 15 patients with post-viral olfactory dysfunction ... acupuncture. These patients were compared with PVOD patients treated ...
... new study of brain activity in depressed and anxious people ... modified for better or for worse by anxiety. ... Behavioral Neuroscience , looked at depression and two types of ... panic; and anxious apprehension, better known as worry. The ...
... ... Mac platforms , ... Richardson, TX (PRWEB) April 1, 2010 -- Damaka, a technology pioneer in Mobile ... Real-time 2-way Video, Application Sharing) Sweeping™ between laptops and mobile devices earlier in May ...
Cached Medicine News:Health News:Palliative Care: Transforming the Care of Serious Illness 2Health News:Palliative Care: Transforming the Care of Serious Illness 3Health News:Demystifying a Common, Persistent Virus 2Health News:FDA, SNM and RSNA host April 13-14 two-topic imaging workshop 2Health News:Depressed? Fearful? It might help to worry, too 2Health News:Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks 2
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
... The Shuttle Relay Suture Passer allows braided ... tissue repair procedures. It may be ... suture material and in conjunction with anchors ... anchor) Additionally, the Shuttle Relay can ...
... EMR Electronic Medical Record organizes communication ... and with outside practitioners. It also ... and other data that traditionally rely ... the patient chart. With Microsoft Outlook ...
Medicine Products: